335.62sirtuininhibitor8.75a 187.67sirtuininhibitor5.03 316.HGF Protein site 88sirtuininhibitor6.28aIntermittent claudication distance (m)Numbness score4.38sirtuininhibitor.
335.62sirtuininhibitor8.75a 187.67sirtuininhibitor5.03 316.88sirtuininhibitor6.28aIntermittent claudication distance (m)Numbness score4.38sirtuininhibitor.65 two.00sirtuininhibitor.91a 4.04sirtuininhibitor.75 2.00sirtuininhibitor.83aComparison of blood pressure, blood sugar and blood lipids in low and highdose subgroups. The values of SBP, DBP, HbA1c, FPG, TG, TC, and LDLC among the low and highdose BMMC subgroups have been not IFN-beta Protein custom synthesis significantly distinct before (W0) and right after (W24) remedy (Psirtuininhibitor0.05). Additionally, there was no substantial difference in every single indicator in between the two subgroups at the very same time point (Psirtuininhibitor0.05; Table V). Comparison of efficacy indicators in low and highdose subgroups. No substantial differences in any from the indicators were detected before (W0) the treatment amongst the low and highdose BMMCs subgroups (Psirtuininhibitor0.05). Just after remedy (W24), the subjective and objective indicators within the two subgroups have been all drastically improved compared with those in the same subgroup at W0 (Psirtuininhibitor0.01). Even so, no important distinction in every indicator between the two subgroups at the identical time point was observed (Psirtuininhibitor0.05; Table VI). Comparison of baseline indicators in SGA and IGA subgroups. The SGA subgroup included 8 males and 8 females (age, 57.69sirtuininhibitor.99 years; disease duration, 17.38sirtuininhibitor.26 years). There were 9 instances with smoking history and 9 situations using a history of alcohol consumption. The BMI was 25.80sirtuininhibitor.72 kg/m 2 as well as the transplantation dose was six.14sirtuininhibitor.25×108 cells. The IGA subgroup included 11 males and ten females (age, 56.14sirtuininhibitor.59 years; disease duration, 15.24sirtuininhibitor.92 years). A total of 12 circumstances had smoking history and 11 cases had a history of alcohol consumption. The BMI was 25.80sirtuininhibitor.08 kg/m two and transplantation dose was 5.79sirtuininhibitor.07×10 8 cells. Sex, age, disease duration, smoking history, alcohol consumption history, BMI and transplantation dose among the two groups were not substantially various (Psirtuininhibitor0.05; Table VII). Comparison of blood pressure, blood sugar and blood lipids within the SGA and IGA subgroups. The values of SBP, HbA1c, FPG, TG, TC and LDLC among the two subgroups have been not significantly distinct just before therapy at W0 (Psirtuininhibitor0.05);Circumstances (n) Time point (weeks)HighdoseLowdoseSubgroupW0 W24 W0 W13 13 245.69sirtuininhibitor.60 3.85sirtuininhibitor.90a 6.13sirtuininhibitor.04 three.83sirtuininhibitor.92aResting discomfort score5.23sirtuininhibitor.88 2.46sirtuininhibitor.13a 5.42sirtuininhibitor.44 two.92sirtuininhibitor.89aLimb coldness scoreTable VIII. Comparison of blood stress, blood sugar and blood lipids amongst the SGA and IGA subgroups prior to and following treatment. HbA1c ( ) SBP (mmHg) DBP (mmHg) TG (mmol/l) TC (mmol/l) LDLC (mmol/l)SubgroupTime pointCasesFPG (mmol/l)SGAIGAW0 W24 W0 W16 16 217.42sirtuininhibitor.65 7.41sirtuininhibitor.73 7.20sirtuininhibitor.62 7.22sirtuininhibitor.6.85sirtuininhibitor.70 6.97sirtuininhibitor.38 6.96sirtuininhibitor.67 7.01sirtuininhibitor.134.50sirtuininhibitor.72 134.75sirtuininhibitor.36 134.71sirtuininhibitor.33 133.24sirtuininhibitor.72.25sirtuininhibitor.49 69.75sirtuininhibitor.53 75.33sirtuininhibitor.77a 74.76sirtuininhibitor.1.76sirtuininhibitor.41 1.88sirtuininhibitor.51 1.94sirtuininhibitor.45 1.85sirtuininhibitor.5.22sirtuininhibitor.44 5.15sirtuininhibitor.46 five.16s.